Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 5/20 | 0.34 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984652 | 1.00 | CNR1 (0.35) | CNR1CNR2ABHD6SSTR4PDE10A | |
| SCHEMBL7694399 | 0.83 | PIK3CD (0.45) | SSTR4IDO1PIK3CD | |
| SCHEMBL21492870 | 0.78 | EPHX2 (0.33) | ACACBPIK3CD | |
| SCHEMBL2633869 | 0.78 | PDE10A (0.58) | PDE10A | |
| SCHEMBL2633870 | 0.78 | PDE10A (0.58) | PDE10A | |
| SCHEMBL9985480 | 0.76 | PDE10A (0.39) | CNR1CNR2SSTR4PDE10A | |
| SCHEMBL2634068 | 0.76 | PDE10A (0.39) | CNR1CNR2SSTR4PDE10A | |
| SCHEMBL24344050 | 0.76 | ACACB (0.36) | PDE10AACACB | |
| SCHEMBL9984507 | 0.76 | PDE10A (0.36) | PDE10APIK3CD | |
| SCHEMBL9984506 | 0.76 | PDE10A (0.36) | PDE10APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | CNR1 2711/4885CNR2 3196/4885ABHD6 347/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | CNR1 2707/4885CNR2 3141/4885ABHD6 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.